Entry Rationale
The current price has broken above the suggested 20-day resistance level of 212.22. Therefore, entry was considered based on confirming whether this resistance level acts as support during a short-term correction.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
MRNAAI Trading Journal · 2026-10-24
Volatile Trading Environment After Breaking Record Highs, Limits and Lessons of Breakout Trading
Moderna gains 14% to set fresh 52-week high
ENTRY PRICE$225.00Entry reference price
AI PREDICTION+2.5%Predicted upside
VERIFIED RESULT-11.1%11.1% down
PREDICTION GAP-13.6%pGap vs. actual result
CONFIDENCE78AI analysis confidence
Moderna's share price surged 14%, hitting a new 52-week high.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
In the event of a short-term correction, we will monitor whether the 20-day resistance line acts as a support level, setting our take-profit target at the resistance level of 212.22 and our stop-loss at the support level of 135.01.
Take-profit reference$212.22
Stop-loss reference$135.01
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$178.99MA60$122.08MA200$71.68
At the time of entry, technical indicators show an RSI (14) of 70.0, a bullish moving average alignment (shortest to longest), trading volume at 2.41 times the 20-day average, and a 7-day rate of change of -3.2%. An RSI of 70.0 indicates entry into the overbought zone, marking a strong upward phase characterized by a significant surge in trading volume to 2.41 times the average and a bullish moving average alignment.
04
HISTORICAL EVIDENCE
Similar Past Cases
Past similar success cases include September 13, 2026 (return rate 128.7%), August 20, 2026 (return rate 125.8%), and August 28, 2026 (return rate 113.7%). These cases are worth referencing based on the selection criterion that the keyword 'Moderna' appears in each.
Reviewing Prediction vs. Actual Result
단기 조정 시 20일 저항선이 지지선으로 작용할 것으로 기대하며 $212.22를 목표로 진입했으나, 실제 결과는 -11.1% 수익률로 손절선에 도달하며 FAILED 판정을 받았습니다. 진입 시점 RSI(14) 70.0의 과매수 구간과 20일평균 대비 2.41배에 달하는 거래량 급증을 동반한 강한 상승 국면이었으나, 이후 주가는 10월 22일(종가 202.63)과 10월 23일(종가 200.1) 급격한 하락세를 보였습니다. 암백신 관련 복합적인 뉴스 흐름 속에서 변동성이 극심해졌고, 저항선을 상향 돌파했던 주가가 지지력을 확보하지 못한 채 하락 압력에 무너진 점을 정확히 예측하지 못했습니다.
What to Watch in the Next Analysis
Based on the failure of this trade, when entering trend-following positions in overbought zones (RSI 70 or above) and during surges in trading volume, we will apply more conservative stop-loss criteria to prepare for short-term volatility and sharp decline risks. Additionally, in volatile market conditions immediately following positive news, we will incorporate an execution plan into our next trades to enter only after more patiently observing the candle patterns to confirm whether resistance levels have definitively turned into support levels.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-10-24
$225.00Verification ChartVerification · 2026-10-24 05:37:40
-11.1%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.